Showing results (1-10 of 51) with videos related to
Sort By:
Pageof 6
Scientifica|November 27, 2013
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical managementAhmad TarhiniCancer Treatment Reviews|October 2, 2018
Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicineAhmad Tarhini, Ragini R KudchadkarJAMA Network Open|November 11, 2021
Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic MelanomaChao Cai, Ismaeel Yunusa, Ahmad TarhiniJournal of Skin Cancer|January 6, 2012
Adjuvant therapy: melanomaDiwakar Davar, Ahmad Tarhini, John M KirkwoodCancer Biotherapy & Radiopharmaceuticals|January 6, 2011
Releasing the brake on the immune system: ipilimumab in melanoma and other tumorsAhmad Tarhini, Ernest Lo, David R MinorExpert Opinion on Investigational Drugs|January 8, 2022
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trialsDanielle K DePalo, Ahmad Tarhini, Jonathan S ZagerThe Oncologist|June 3, 2021
Multidisciplinary Care of BRAF-Mutant Stage III Melanoma: A Physicians Perspective ReviewLynn A Cornelius, Ryan C Fields, Ahmad TarhiniPhytotherapy Research : PTR|June 4, 2005
The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive ratsZahra Fatehi-Hassanabad, Mostafa Jafarzadeh, Ahmad Tarhini, et al.Seminars in Immunopathology|February 1, 2011
Prognostic significance of autoimmunity during treatment of melanoma with interferonMichal T Krauze, Ahmad Tarhini, Helen Gogas, et al.Journal of Comparative Effectiveness Research|November 29, 2019
Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanomaRohini Sharma, Roy Koruth, Steve Kanters, et al.Pageof 6